Acetyl‐L‐carnitine for patients with hepatic encephalopathy
References
Additional references
Als‐Nielsen B, Koretz RL, Gluud LL, Gluud C. Branched‐chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001939]
Als‐Nielsen B, Gluud LL, Gluud C. Dopaminergic agonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003047.pub2]
Als‐Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD002798.pub2]
Als‐Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003044.pub2]
Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401‐6. [PUBMED: 21208779]
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9. [PUBMED: 18411040]
Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98. [PUBMED: 18824466]
Ciapponi A, Glujovsky D, Bardach A, García Martí S, Comande D. EROS: a new software for early stage of systematic reviews. ISPOR 3rd Latin America Conference. Mexico City: Hilton Mexico City Reforma, 2011.
Conn HO. Trailmaking and number‐connection tests in the assessment of mental state in portal systemic encephalopathy. American Journal of Digestive Diseases 1977;22(6):541‐50. [PUBMED: 868833]
Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 10 July 2014).
Falavigna M, Kieling C, Wolff FH, Medeiros LRF, Cheinquer H. Antibiotics for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006314]
Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nature Reviews. Neuroscience 2013;14(12):851‐8. [PUBMED: 24149188]
Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterology & Hepatology 2011;7(4):222‐33. [PUBMED: 21857820]
Frontera JA. Management of hepatic encephalopathy. Current Treatment Options in Neurology 2014;16(6):297. [PUBMED: 24807164]
Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als‐Nielsen B, Colli A, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 6. Art. No.: LIVER.
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology 2011;64(12):1283‐93. [PUBMED: 21839614]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302. [PUBMED: 21803546]
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology 2011;64(12):1277‐82. [PUBMED: 21802904]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology 2011;64(12):1303‐10. [PUBMED: 21802903]
Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso‐Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311‐6. [PUBMED: 21802902]
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso‐Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407‐15. [PUBMED: 21247734]
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [PUBMED: 21195583]
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395‐400. [PUBMED: 21194891]
Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles‐continuous outcomes. Journal of Clinical Epidemiology 2013;66(2):173‐83. [PUBMED: 23116689]
Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158‐72. [PUBMED: 22609141]
Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151‐7. [PUBMED: 22542023]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. [PUBMED: 12958120]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.) 1999;319(7211):670‐4. [PUBMED: 10480822]
International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997.
Jiang Q, Jiang G, Shi KQ, Cai H, Wang YX, Zheng MH. Oral acetyl‐L‐carnitine treatment in hepatic encephalopathy: view of evidence‐based medicine. Annals of Hepatology 2013;12(5):803‐9. [PUBMED: 24018499]
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. [PUBMED: 11730399]
Krähenbühl S. Carnitine metabolism in chronic liver disease. Life Sciences 1996;59(19):1579‐99. [PUBMED: 8913324]
Krähenbühl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 1997;25(1):148‐53. [PUBMED: 8985281]
Lan GKK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70(3):659‐63. [DOI: 10.1093/biomet/70.3.659]
Liou IW. Management of end‐stage liver disease. Medical Clinics of North America 2014;98(1):119‐52. [PUBMED: 24266918]
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
Malaguarnera M, Pistone G, Astuto M, Dell'Arte S, Finocchiaro G, Lo Giudice E, et al. L‐carnitine in the treatment of mild or moderate hepatic encephalopathy. Digestive Diseases 2003;21(3):271‐5. [PUBMED: 14571103]
Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L‐carnitine in patients with hepatic encephalopathy. World Journal of Gastroenterology 2005;11(45):7197‐202. [PUBMED: 16437672]
Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, et al. Effects of L‐acetylcarnitine on cirrhotic patients with hepatic coma: randomized double‐blind, placebo‐controlled trial. Digestive Diseases and Sciences 2006;51(12):2242‐7. [PUBMED: 17080254]
Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, et al. Acetyl‐L‐carnitine treatment in minimal hepatic encephalopathy. Digestive Diseases and Sciences 2008;53(11):3018‐25. [PUBMED: 18357530]
Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, et al. Acetyl‐L‐carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metabolic Brain Disease 2011;26(4):281‐9. [PUBMED: 21870121]
Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, et al. Acetyl‐L‐carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scandinavian Journal of Gastroenterology 2011;46(6):750‐9. [PUBMED: 21443422]
Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, et al. Oral acetyl‐L‐carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double‐blind, placebo‐controlled study. American Journal of Clinical Nutrition 2011;93(4):799‐808. [PUBMED: 21310833]
Malaguarnera M. Carnitine derivatives: clinical usefulness. Current Opinion in Gastroenterology 2012;28(2):166‐76. [PUBMED: 22333562]
Malaguarnera M. Acetyl‐L‐carnitine in hepatic encephalopathy. Metabolic Brain Disease 2013;28(2):193‐9. [PUBMED: 23389620]
McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD008716.pub2]
McPhail MJ, Bajaj JS, Thomas HC, Taylor‐Robinson SD. Pathogenesis and diagnosis of hepatic encephalopathy. Expert Review of Gastroenterology & Hepatology 2010;4(3):365‐78. [PUBMED: 20528123]
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. [PUBMED: 9746022]
Munoz SJ. Hepatic encephalopathy. Medical Clinics of North America 2008;92(4):795‐812, viii. [PUBMED: 18570943]
Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology 2013;66(7):736‐42; quiz 742.e1‐5. [PUBMED: 23623694]
Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World Journal of Gastroenterology 2014;20(18):5442‐60. [PUBMED: 24833875]
Perazzo JC, Tallis S, Delfante A, Souto PA, Lemberg A, Eizayaga FX, et al. Hepatic encephalopathy: an approach to its multiple pathophysiological features. World Journal of Hepatology 2012;4(3):50‐65. [PUBMED: 22489256]
Poordad FF. Review article: the burden of hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2007;25(Suppl 1):3‐9.
Rahimi RS, Rockey DC. End‐stage liver disease complications. Current Opinion in Gastroenterology 2013;29(3):257‐63. [PUBMED: 23429468]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Romero‐Gomez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute on chronic liver failure. Journal of Hepatology2014; Vol. pii:S0168‐8278(14)00646‐1. [PUBMED: 25218789]
Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429‐38. [PUBMED: 22945832]
Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment 2012;16(35):1‐82. [PUBMED: 22989478]
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [PUBMED: 7823387]
Selimoglu MA, Aydogdu S, Yagci RV, Huseyinov A. Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. Pediatrics International 2001;43(4):391‐5. [PUBMED: 11472585]
Shores NJ, Keeffe EB. Is oral L‐acyl‐carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Digestive Diseases and Sciences 2008;53(9):2330‐3. [PUBMED: 18270833]
Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In‐hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clinical Gastroenterology and Hepatology 2012;10(9):1034‐41.e1. [PUBMED: 22642955]
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ (Clinical Research Ed.) 2011;343:d4002. [PUBMED: 21784880]
Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Review of Gastroenterology & Hepatology 2014;8(1):83‐100. [PUBMED: 24236755]
Sun SL, Yang KH, Jing T, Zhang J, Tian JH, Ma B, et al. Naloxone for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008177]
Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Medical Clinics of North America 2009;93(4):819‐36, vii. [PUBMED: 19577116]
Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses. International Journal of Epidemiology 2009;38(1):276‐86.
Thorlund K, Anema A, Mills E. Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology 2010;2:57‐66.
Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 10 July 2014).
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60(2):715‐35. [PUBMED: 25042402]
Wakim‐Fleming J. Hepatic encephalopathy: suspect it early in patients with cirrhosis. Cleveland Clinic Journal of Medicine 2011;78(9):597‐605. [PUBMED: 21885692]
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. [PUBMED: 18083463]
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080]
Wong RJ, Gish RG, Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transplantation 2014;20(12):1454‐61. [PUBMED: 25155379]
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601‐5. [PUBMED: 18316340]
Zavala D, Martí A, Peña‐Martí G, Comunián G. Sheet to enter data for performing a Cochrane review. Valencia, Venezuela: Universidad de Carabobo, 2006.
